In this video, we see an excellent example of how a well-designed future product led to this product becoming not just a marketing support for Guinness beer, but a completely separate product category spin-off, independent of the beer itself. And, just like more than 70 years ago, today, the Guinness World Records is not only the main player in this category, but in fact a trendsetter.
The New Spinoff Market is coming: Foundation Robotics, a U.S.-based startup developing humanoid robots for military applications, has recently sent their Phantom MK1 robots to Ukraine for testing.
The company is preparing its humanoid robots for potential deployment in war for the Pentagon as well, which "continues to explore the development of militarized humanoid prototypes designed to operate alongside warfighters in complex, high-risk environments."
Foundation co-founder also said the that they are in "very close contact" with the Pentagon regarding using their humanoid for possible patrol functions along the U.S. southern border. The testing in Ukraine will be a big step forward.
The company is preparing its humanoid robots for potential deployment in war for the Pentagon as well, which "continues to explore the development of militarized humanoid prototypes designed to operate alongside warfighters in complex, high-risk environments."
Foundation co-founder also said the that they are in "very close contact" with the Pentagon regarding using their humanoid for possible patrol functions along the U.S. southern border. The testing in Ukraine will be a big step forward.
From a Dog’s Tumor to a New Bioeconomic Frontier: The Rise of the Personalized Cancer Vaccine Market
When an Australian technology entrepreneur faced the devastating diagnosis of aggressive cancer in his rescue dog, the solution he pursued would have seemed like science fiction only a decade ago. Instead of relying solely on conventional veterinary oncology, he turned to genomic sequencing, artificial intelligence, and mRNA biotechnology to design a custom cancer vaccine from scratch.
What followed is not just a remarkable medical story—it is also a glimpse into what could become a new spinoff market in biotechnology, potentially reshaping both oncology and the economics of personalized medicine.
A Case Study in Hyper-Personalized Medicine
The experiment began after a dog named Rosie developed an aggressive mast cell tumor. Standard treatments failed to halt the disease. Faced with limited options, her owner, Australian tech entrepreneur Paul Conyngham, decided to pursue an unconventional path.
He had Rosie’s tumor DNA sequenced—an increasingly accessible process that cost about $3,000. The genetic data was then analyzed using advanced AI tools, including ChatGPT and AlphaFold.
From this analysis, researchers identified neoantigens—mutated proteins unique to the tumor. These molecular fingerprints became the blueprint for a bespoke mRNA vaccine designed specifically to train the immune system to attack Rosie’s cancer cells.
The result: after treatment, the tumor reportedly shrank by about 50%, and Rosie recovered to a stable condition.
Scientists involved in the effort, including researchers at the UNSW RNA Institute, describe the case as a demonstration of how quickly personalized immunotherapy can now be developed.
How Personalized mRNA Cancer Vaccines Work
Traditional cancer treatments—chemotherapy, radiation, and even many targeted drugs—are designed for broad categories of disease. Personalized cancer vaccines operate on a radically different principle: every tumor is genetically unique.
The process generally involves several stages:
Tumor sequencing
DNA from a patient’s tumor is sequenced to identify mutations.
Neoantigen discovery
Algorithms identify mutations likely to produce abnormal proteins recognizable by the immune system.
Vaccine design
mRNA molecules are engineered to encode those tumor-specific neoantigens.
Immune activation
Once injected, cells produce the encoded proteins, prompting the immune system to recognize and attack the cancer.
The concept builds directly on the mRNA platform popularized during the COVID-19 pandemic by companies such as Moderna and BioNTech.
What is different here is extreme personalization: the therapy is designed for one patient, one tumor, one immune response.
AI as the Catalyst
The reason this approach is suddenly feasible lies in the convergence of three technologies:
Cheap genomic sequencing
Protein-structure AI models
Rapid mRNA synthesis
AI tools dramatically accelerate the process of predicting which tumor mutations will produce viable immune targets. Systems like AlphaFold help researchers understand protein structures, while language-model-based systems such as ChatGPT can assist with data interpretation, hypothesis generation, and workflow integration.
What once required years of lab work can now occur within weeks.
The Emergence of a New Spinoff Market
Beyond the scientific implications lies a potentially massive economic transformation.
The convergence of AI, genomics, and mRNA platforms may create a new spinoff market in medicine: the personalized cancer vaccine industry.
This future spinoff market could resemble a hybrid of:
biotechnology
software platforms
precision diagnostics
distributed pharmaceutical manufacturing
Instead of blockbuster drugs manufactured for millions of patients, the model shifts toward micro-manufacturing individualized therapies.
When an Australian technology entrepreneur faced the devastating diagnosis of aggressive cancer in his rescue dog, the solution he pursued would have seemed like science fiction only a decade ago. Instead of relying solely on conventional veterinary oncology, he turned to genomic sequencing, artificial intelligence, and mRNA biotechnology to design a custom cancer vaccine from scratch.
What followed is not just a remarkable medical story—it is also a glimpse into what could become a new spinoff market in biotechnology, potentially reshaping both oncology and the economics of personalized medicine.
A Case Study in Hyper-Personalized Medicine
The experiment began after a dog named Rosie developed an aggressive mast cell tumor. Standard treatments failed to halt the disease. Faced with limited options, her owner, Australian tech entrepreneur Paul Conyngham, decided to pursue an unconventional path.
He had Rosie’s tumor DNA sequenced—an increasingly accessible process that cost about $3,000. The genetic data was then analyzed using advanced AI tools, including ChatGPT and AlphaFold.
From this analysis, researchers identified neoantigens—mutated proteins unique to the tumor. These molecular fingerprints became the blueprint for a bespoke mRNA vaccine designed specifically to train the immune system to attack Rosie’s cancer cells.
The result: after treatment, the tumor reportedly shrank by about 50%, and Rosie recovered to a stable condition.
Scientists involved in the effort, including researchers at the UNSW RNA Institute, describe the case as a demonstration of how quickly personalized immunotherapy can now be developed.
How Personalized mRNA Cancer Vaccines Work
Traditional cancer treatments—chemotherapy, radiation, and even many targeted drugs—are designed for broad categories of disease. Personalized cancer vaccines operate on a radically different principle: every tumor is genetically unique.
The process generally involves several stages:
Tumor sequencing
DNA from a patient’s tumor is sequenced to identify mutations.
Neoantigen discovery
Algorithms identify mutations likely to produce abnormal proteins recognizable by the immune system.
Vaccine design
mRNA molecules are engineered to encode those tumor-specific neoantigens.
Immune activation
Once injected, cells produce the encoded proteins, prompting the immune system to recognize and attack the cancer.
The concept builds directly on the mRNA platform popularized during the COVID-19 pandemic by companies such as Moderna and BioNTech.
What is different here is extreme personalization: the therapy is designed for one patient, one tumor, one immune response.
AI as the Catalyst
The reason this approach is suddenly feasible lies in the convergence of three technologies:
Cheap genomic sequencing
Protein-structure AI models
Rapid mRNA synthesis
AI tools dramatically accelerate the process of predicting which tumor mutations will produce viable immune targets. Systems like AlphaFold help researchers understand protein structures, while language-model-based systems such as ChatGPT can assist with data interpretation, hypothesis generation, and workflow integration.
What once required years of lab work can now occur within weeks.
The Emergence of a New Spinoff Market
Beyond the scientific implications lies a potentially massive economic transformation.
The convergence of AI, genomics, and mRNA platforms may create a new spinoff market in medicine: the personalized cancer vaccine industry.
This future spinoff market could resemble a hybrid of:
biotechnology
software platforms
precision diagnostics
distributed pharmaceutical manufacturing
Instead of blockbuster drugs manufactured for millions of patients, the model shifts toward micro-manufacturing individualized therapies.
Key components of the emerging spinoff market
AI-driven neoantigen discovery platforms
Rapid sequencing services
On-demand mRNA manufacturing
Clinical delivery networks
Regulatory frameworks for individualized therapeutics
Each layer represents a potential spinoff market opportunity for startups and pharmaceutical companies.
Economic Scale: From Veterinary Medicine to Human Oncology
Cancer remains one of the largest markets in global healthcare. The global oncology market already exceeds $200 billion annually, and personalized immunotherapies could expand that dramatically.
If individualized mRNA vaccines become routine, the new spinoff market may evolve toward a platform economy rather than a drug-product economy.
In such a system:
sequencing companies supply genomic data
AI platforms design therapeutic targets
pharmaceutical manufacturers produce individualized mRNA payloads
hospitals function as local delivery nodes
The economic structure begins to resemble cloud computing for medicine—a decentralized pipeline where data becomes the primary input.
Regulatory and Technical Barriers
Despite the promise, several major challenges remain:
Regulatory frameworks
Current drug approval systems are designed for standardized medicines, not individualized therapies.
Manufacturing logistics
Producing thousands of unique mRNA formulations requires new industrial processes.
Cost management
Even if sequencing becomes cheap, production and clinical validation must become scalable.
Clinical evidence
Large human trials are still needed to validate long-term effectiveness.
Why This Case Matters
Rosie the dog may represent more than an anecdote—it could be a prototype for the future of oncology.
Her treatment illustrates how rapidly biotechnology is shifting from population-scale medicine to algorithm-designed therapeutics.
If the underlying technologies mature, the world could see the rise of a global personalized immunotherapy spinoff market, where cancer vaccines are designed in days, manufactured locally, and tailored to each patient’s unique tumor biology.
In that future, the boundary between software engineering and pharmaceutical development may become increasingly blurred.
And the unlikely origin story of that transformation might trace back to a dog whose tumor sequence was uploaded into an AI system—and turned into a lifesaving vaccine.
About the commercial potential of this new spinoff market. As personalized mRNA cancer vaccines mature, they unlock significant opportunities for startups. First, companies focused on AI-driven neoantigen discovery can become key platforms, offering scalable software tools that democratize access to personalized therapy design. Similarly, sequencing companies that specialize in rapid, cost-effective tumor analysis will see explosive growth. Moreover, biotechs that build agile, on-demand mRNA manufacturing capabilities will become crucial, offering bespoke production at scale.
From an investment perspective, this spinoff market promises substantial returns. Venture capitalists have a unique window to fund AI-driven platforms, sequencing services, and decentralized mRNA production networks. As regulatory frameworks evolve to accommodate individualized therapies, these startups will be able to commercialize their services to a global market. Ultimately, this convergence of AI, genomics, and mRNA could create a multi-billion dollar industry, where patient-specific therapies are not just a niche, but a cornerstone of next-generation oncology care.
Investors can look at several concrete project types within this emerging spinoff market. First, they can fund AI-based neoantigen discovery platforms—companies that automate the identification of optimal tumor targets. Second, they can invest in rapid, cloud-based sequencing services that allow oncologists and veterinarians to get personalized data within days. Third, startups that specialize in on-demand mRNA manufacturing will be crucial—they can provide tailored vaccines for individual patients quickly and cost-effectively.
AI-driven neoantigen discovery platforms
Rapid sequencing services
On-demand mRNA manufacturing
Clinical delivery networks
Regulatory frameworks for individualized therapeutics
Each layer represents a potential spinoff market opportunity for startups and pharmaceutical companies.
Economic Scale: From Veterinary Medicine to Human Oncology
Cancer remains one of the largest markets in global healthcare. The global oncology market already exceeds $200 billion annually, and personalized immunotherapies could expand that dramatically.
If individualized mRNA vaccines become routine, the new spinoff market may evolve toward a platform economy rather than a drug-product economy.
In such a system:
sequencing companies supply genomic data
AI platforms design therapeutic targets
pharmaceutical manufacturers produce individualized mRNA payloads
hospitals function as local delivery nodes
The economic structure begins to resemble cloud computing for medicine—a decentralized pipeline where data becomes the primary input.
Regulatory and Technical Barriers
Despite the promise, several major challenges remain:
Regulatory frameworks
Current drug approval systems are designed for standardized medicines, not individualized therapies.
Manufacturing logistics
Producing thousands of unique mRNA formulations requires new industrial processes.
Cost management
Even if sequencing becomes cheap, production and clinical validation must become scalable.
Clinical evidence
Large human trials are still needed to validate long-term effectiveness.
Why This Case Matters
Rosie the dog may represent more than an anecdote—it could be a prototype for the future of oncology.
Her treatment illustrates how rapidly biotechnology is shifting from population-scale medicine to algorithm-designed therapeutics.
If the underlying technologies mature, the world could see the rise of a global personalized immunotherapy spinoff market, where cancer vaccines are designed in days, manufactured locally, and tailored to each patient’s unique tumor biology.
In that future, the boundary between software engineering and pharmaceutical development may become increasingly blurred.
And the unlikely origin story of that transformation might trace back to a dog whose tumor sequence was uploaded into an AI system—and turned into a lifesaving vaccine.
About the commercial potential of this new spinoff market. As personalized mRNA cancer vaccines mature, they unlock significant opportunities for startups. First, companies focused on AI-driven neoantigen discovery can become key platforms, offering scalable software tools that democratize access to personalized therapy design. Similarly, sequencing companies that specialize in rapid, cost-effective tumor analysis will see explosive growth. Moreover, biotechs that build agile, on-demand mRNA manufacturing capabilities will become crucial, offering bespoke production at scale.
From an investment perspective, this spinoff market promises substantial returns. Venture capitalists have a unique window to fund AI-driven platforms, sequencing services, and decentralized mRNA production networks. As regulatory frameworks evolve to accommodate individualized therapies, these startups will be able to commercialize their services to a global market. Ultimately, this convergence of AI, genomics, and mRNA could create a multi-billion dollar industry, where patient-specific therapies are not just a niche, but a cornerstone of next-generation oncology care.
Investors can look at several concrete project types within this emerging spinoff market. First, they can fund AI-based neoantigen discovery platforms—companies that automate the identification of optimal tumor targets. Second, they can invest in rapid, cloud-based sequencing services that allow oncologists and veterinarians to get personalized data within days. Third, startups that specialize in on-demand mRNA manufacturing will be crucial—they can provide tailored vaccines for individual patients quickly and cost-effectively.
Fourth, companies developing regulatory compliance solutions for personalized therapies will be in demand, ensuring these bespoke treatments clear regulatory hurdles faster. Finally, investing in clinical delivery networks—platforms that facilitate rapid, local administration of these personalized vaccines—could yield high returns. In short, by targeting these verticals—AI discovery, sequencing, manufacturing, and regulatory innovation—investors can position themselves in what could become a multi-billion dollar, patient-specific therapeutic market.
For a example: startup called Neon Therapeutics. They began by focusing on identifying neoantigens in individual tumors, using high-throughput sequencing combined with AI algorithms. Structurally, they raised an initial $60 million in venture capital to build their AI platform for neoantigen discovery. Today, they partner with major biopharma firms, offering a suite of solutions: once a tumor is sequenced, Neon’s AI identifies targets, and their team develops a bespoke mRNA vaccine. Currently, they are in late-stage clinical trials for a range of cancers, demonstrating measurable tumor regression in early human studies. Thus, their business model bridges cutting-edge science and applied therapeutics, positioning them to become a major player in the personalized oncology space.
Certainly. One of the critical advantages for startups like Neon Therapeutics is that animal models, particularly companion animals like dogs, face significantly less regulatory burden than human clinical trials. This allows them to serve as a powerful proof of concept. By testing their personalized mRNA vaccines on naturally occurring cancers in pets, startups can generate robust, real-world data quickly. These animal studies act as a proof of concept, demonstrating safety and efficacy in a clinical setting well before human trials. Thus, they can bring a real therapeutic solution to market faster—offering customized cancer treatments for animals today, while simultaneously building a validated platform that they can later adapt for human oncology. In this way, the reduced entry barriers in the animal market create a more accessible pathway to commercialization, giving investors a tangible, near-term product while paving the way for future human applications.
As this growing spinoff market matures and the design of personalized cancer vaccines for companion animals is fully established, with all regulatory barriers cleared, the valuation potential is immense. Analysts project that, in the next 10 to 20 years, this market could reach tens of billions of dollars globally. Once human clinical trials validate these approaches, the market could expand even further—potentially mirroring or surpassing the broader oncology market, which is already worth over $200 billion annually. Thus, for investors, this spinoff market is poised to become a cornerstone of the next generation of both veterinary and human oncology, offering unprecedented growth potential in the next two decades.
For a example: startup called Neon Therapeutics. They began by focusing on identifying neoantigens in individual tumors, using high-throughput sequencing combined with AI algorithms. Structurally, they raised an initial $60 million in venture capital to build their AI platform for neoantigen discovery. Today, they partner with major biopharma firms, offering a suite of solutions: once a tumor is sequenced, Neon’s AI identifies targets, and their team develops a bespoke mRNA vaccine. Currently, they are in late-stage clinical trials for a range of cancers, demonstrating measurable tumor regression in early human studies. Thus, their business model bridges cutting-edge science and applied therapeutics, positioning them to become a major player in the personalized oncology space.
Certainly. One of the critical advantages for startups like Neon Therapeutics is that animal models, particularly companion animals like dogs, face significantly less regulatory burden than human clinical trials. This allows them to serve as a powerful proof of concept. By testing their personalized mRNA vaccines on naturally occurring cancers in pets, startups can generate robust, real-world data quickly. These animal studies act as a proof of concept, demonstrating safety and efficacy in a clinical setting well before human trials. Thus, they can bring a real therapeutic solution to market faster—offering customized cancer treatments for animals today, while simultaneously building a validated platform that they can later adapt for human oncology. In this way, the reduced entry barriers in the animal market create a more accessible pathway to commercialization, giving investors a tangible, near-term product while paving the way for future human applications.
As this growing spinoff market matures and the design of personalized cancer vaccines for companion animals is fully established, with all regulatory barriers cleared, the valuation potential is immense. Analysts project that, in the next 10 to 20 years, this market could reach tens of billions of dollars globally. Once human clinical trials validate these approaches, the market could expand even further—potentially mirroring or surpassing the broader oncology market, which is already worth over $200 billion annually. Thus, for investors, this spinoff market is poised to become a cornerstone of the next generation of both veterinary and human oncology, offering unprecedented growth potential in the next two decades.